Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRADOR ctDNA-guided treatment study in HR-positive/HER2-negative early breast cancer
2023-505661-89-00Phase 2Suspended
- Sponsor
- MEDSIR
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of abemaciclib, giredestrant and inavolisib in breast cancer (5 arms), sponsored by MEDSIR. Started Apr 2024; status: suspended.
02
Drugs
abemaciclibgiredestrantinavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505661-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505661-89-00.